Phibro Animal Health (Phibro Animal Health) Debt-to-Equity

: 1.90 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Phibro Animal Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $33.0 Mil. Phibro Animal Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $480.0 Mil. Phibro Animal Health's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $270.8 Mil. Phibro Animal Health's debt to equity for the quarter that ended in Dec. 2023 was 1.89.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Phibro Animal Health's Debt-to-Equity or its related term are showing as below:

PAHC' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.76 Med: 1.92 Max: 19.1
Current: 1.9

During the past 13 years, the highest Debt-to-Equity Ratio of Phibro Animal Health was 19.10. The lowest was -4.76. And the median was 1.92.

PAHC's Debt-to-Equity is ranked worse than
94.87% of 858 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs PAHC: 1.90

Phibro Animal Health Debt-to-Equity Historical Data

The historical data trend for Phibro Animal Health's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

1.51

2.18

1.79

1.81

Phibro Animal Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																1.91	1.90	1.81	1.90	1.90

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phibro Animal Health Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Debt-to-Equity falls into.

Phibro Animal Health Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Phibro Animal Health's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(28.348	+	481.618)	/	282.509
	=	1.81

Phibro Animal Health's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(33.048	+	480.046)	/	270.803
	=	1.89

Phibro Animal Health (NAS:PAHC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Phibro Animal Health Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Phibro Animal Health (Phibro Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PB8:Germany

Address

300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712

Website

https://www.pahc.com

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Executives

Judith Weinstein	officer: See Remarks	C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran	director
Larry Lee Miller	officer: Chief Operating Officer	8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio	officer: Chief Financial Officer	C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman	officer: President,North America Region	C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim	director, officer: Exec. VP, Corporate Strategy	300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras	officer: Pres Animal Health & Nutr N.A.	5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim	director, 10 percent owner, officer: President and CEO	C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc	10 percent owner	300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim	director	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino	officer: SEE REMARKS	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson	officer: Chief Financial Officer	7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson	director	2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger	officer: SVP, Gen Counsel and Corp Sec	41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046